In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Australia is home to some truly unique and unexpected creatures, but few are quite as strange and fascinating as the platypus ...

BMI falls short as a way to measure obesity. Doctors need to also determine whether body fat harms a person's health.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?